YARROW BIOSCIENCE, INC. Business Acquisition, Pro Forma Revenue
YARROW BIOSCIENCE, INC. (YARW) reported Business Acquisition, Pro Forma Revenue of $20.99 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-17.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2022-03-17
- YARROW BIOSCIENCE, INC. business acquisition, pro forma revenue for the quarter ending 2020-12-31 was $4.29M, a 3074.81% increase year-over-year.
- YARROW BIOSCIENCE, INC. business acquisition, pro forma revenue for the quarter ending 2020-09-30 was $3.27M.
- YARROW BIOSCIENCE, INC. business acquisition, pro forma revenue for the quarter ending 2020-06-30 was $11.69M.
- YARROW BIOSCIENCE, INC. business acquisition, pro forma revenue for the quarter ending 2020-03-31 was $1.75M, a 468.18% increase year-over-year.
- YARROW BIOSCIENCE, INC. business acquisition, pro forma revenue for fiscal 2020 was $20.99M, a 4638.83% increase from fiscal 2019.
- YARROW BIOSCIENCE, INC. business acquisition, pro forma revenue for fiscal 2019 was $443.00K.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2020-12-31 | $4.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $7.55M derived: sum of 2 quarters · filed 2022-03-17 | $19.24M derived: sum of 3 quarters · filed 2022-03-17 | $20.99M 10-K · filed 2022-03-17 |
| 2020-09-30 | $3.27M 10-Q · filed 2021-11-10 | $14.96M derived: sum of 2 quarters · filed 2021-11-10 | $16.71M 10-Q · filed 2021-11-10 | $16.84M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $11.69M 10-Q · filed 2021-08-12 | $13.44M 10-Q · filed 2021-08-12 | $13.57M derived: sum of 3 quarters · filed 2021-08-12 | $13.57M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $1.75M 10-Q · filed 2021-05-06 | $1.89M derived: sum of 2 quarters · filed 2021-05-06 | $1.89M derived: sum of 3 quarters · filed 2021-05-06 | $1.89M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $135.00K derived: sum of 2 quarters · filed 2021-03-04 | $135.00K derived: sum of 3 quarters · filed 2021-03-04 | $443.00K 10-K · filed 2021-03-04 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $308.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-06 | $308.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $308.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |